UK Adult Malignant Glioma Therapeutics Market Analysis

UK Adult Malignant Glioma Therapeutics Market Executive Summary

The UK Adult Glioma Therapeutics Market is valued at around $57 Mn in 2022 and is projected to reach $98 Mn by 2030, exhibiting a CAGR of 6.9% during the forecast period.

Malignant glioma is a type of brain cancer that originates from glial cells in the central nervous system. These supporting cells can turn into tumours called gliomas, known for their aggressive nature. The three main types in adults are anaplastic astrocytoma, anaplastic oligodendroglioma, and glioblastoma multiforme (GBM). Treatment typically involves a combination of radiation therapy, chemotherapy, and surgery. Due to their aggressiveness, the prognosis for malignant gliomas is often uncertain, influenced by factors like the patient's age, tumor size and location, and how well the tumor responds to treatment.

The Glioma incidence rates vary across the UK, with greater rates in Northern Ireland and Scotland than in England and Wales. Every year, around 4,300 individuals are diagnosed with Gliomas, with GBM accounting for nearly 60% of cases. This amounts to 12 per 100,000 individuals encountering GBM each year, which is higher than the global standard. It should also be highlighted that by 2030, more than 20% of the UK population will be 65 or older, which will significantly raise the risk of Glioma, given that the average age at diagnosis is 64. The UK Adult Malignant Glioma Therapeutics Market is being driven by a compelling confluence of factors, including an increasing Glioma burden, an aging population, a focus on customized therapy, and active research and development initiatives, both by the government and other market players.

Switzerland-based pharmaceutical company Roche has the biggest market share with Avastin (Bevacizumab), a critical drug used for recurrent GBM& in the UK, while Merck & Co. dominates the first-line treatment market for Glioma& with Temozolomide.

Market Dynamics

Market Growth Drivers

Reimbursement Landscape: While the NHS provides coverage for proven treatments such as Temozolomide and radiation, access to newer, targeted medicines like immunotherapy may be limited by cost and availability. This leaves a void in the market for affordable and accessible treatment choices.

Increased Focus on Research: The UK has a thriving clinical trial environment for glioma treatments, with over 80 studies now underway. This investment in R&D promotes innovation and offers the potential for future breakthroughs. Initiatives such as the 100,000 Genomes Project are opening the road for personalized therapy in glioma, enabling targeted treatments based on specific tumour mutations. This tailored strategy has the potential to enhance treatment results and increase market demand for specialized medications.

Increased Public Awareness: Increased public awareness of cancer and enhanced cancer screening programs result in earlier detection and treatment. The advances in supportive care and palliative therapies enable glioma patients to survive longer and with higher quality of life, resulting in a longer-term need for medicines. These factors act as drivers for market growth.

Market Restraints

Shortage of Staff and Healthcare Workers: The existing lack of numerous healthcare professions, including oncologists, nurses, and specialist technicians, is already limiting the NHS's ability to provide appropriate treatment for cancer patients. With a limited workforce, hospitals may struggle to offer the extensive and specialized care that glioma patients require while undergoing sophisticated therapies such as surgery, radiation, and immunotherapy.

Existing Healthcare Burden: The NHS is already under enormous strain because to an aging population, an increasing chronic illness load, and excessive wait times. Integrating and supporting costly novel glioma treatments such as targeted medicines and immunotherapies in this overburdened system will be difficult and time-consuming. Thus, immediate market expansion cannot be assured.

Psychological Burden of Glioma: Patients with glioma have emotional anguish, cognitive impairments, and a worse quality of life as a result of the disease's aggressiveness and treatment complications. Inadequate access to supportive care services and psychological assistance can have a negative influence on patient well-being and treatment compliance.

Healthcare Policies and Regulatory Landscape

The National Health Service (NHS) of the United Kingdom has developed a variety of regulations and standards to protect patient rights, privacy, and public involvement. The NHS Constitution for England specifies patient, public, and worker rights, as well as the NHS's commitments. It emphasizes the ability to select healthcare providers, access to information, and the NHS's core principles and values. The Medicines and Healthcare Products Regulatory Agency (MHRA), an executive agency of the Department of Health and Social Care in the UK, is responsible for ensuring that pharmaceuticals and medical equipment perform properly and are fairly safe. The MHRA's multiple independent advisory groups provide the UK government with information and suggestions on pharmaceutical and medical device regulation. In the UK, there are many regulatory avenues for medication approval, each with its own set of standards and timescales. While there are expedited options for high-priority pharmaceuticals or public health emergencies, the standard process might take years.

Competitive Landscape

Key Players

• Merck & Co.
• Bristol-Myers Squibb
• Roche
• AbbVie
• Azurity Pharmaceuticals
• Aptevo Therapeutics
• Peptinib Ltd.
• Bio-Rad Laboratories
• Novocure
• Pfizer